Cosmos Health reports CosmoFarm growth: what it means for Cosmos Health stock

Published on 10/05/2026 at 02:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cosmos Health stock was last at EUR 0.29 on September 18, 2026. Second-quarter revenue reached USD 19.32 million versus USD 18.99 million consensus.

COSM, US2214133058, Illustration mit AI erstellt.

Cosmos Health reported record CosmoFarm revenue above USD 15.00 million in the second quarter of 2026, lifting the subsidiary's annualized run-rate above USD 60.00 million. The update appeared in a September 29, 2026 release carried by Yahoo Finance. The figures give Cosmos Health stock a concrete operating metric as the company expands pharmaceutical distribution and contract manufacturing.

CosmoFarm clears USD 60 million run-rate

CosmoFarm's second-quarter revenue translated into an annualized run-rate above USD 60.00 million, while the subsidiary had generated approximately USD 14.00 million in fiscal year 2017 before the acquisition. The comparison shows the scale of the unit's expansion, although the run-rate is not the same as recognized annual revenue.

Cosmos Health also said its broader platform includes more than 15 proprietary brands and product lines, 10 branded generics and sales across more than 40 countries. StockTitan reported these portfolio details on October 1, 2026, including a contract-manufacturing pipeline above 32.70 million units.

Quarterly revenue beat consensus

The most recent reported quarter also provides a comparison for the growth narrative. According to MarketBeat, Cosmos Health reported USD 19.32 million in revenue for the quarter released on August 19, 2026, versus consensus of USD 18.99 million. Earnings per share were a loss of USD 0.10, matching consensus, while net margin was negative 33.08 percent.

The counterweight is profitability. MarketBeat lists a market capitalization of USD 38.24 million on its page, while the finance quote showed USD 20.7 million as of October 2, 2026. The difference reflects separate market-data snapshots, so the figures are not combined into one valuation claim.

Stock remains below yearly high

On the Nasdaq, COSM closed at USD 0.38 on October 2, 2026, versus a prior close of USD 0.39. The 52-week range was USD 0.16 to USD 1.32, placing the stock well below its yearly high and leaving operating execution as the central valuation question.

The last euro quotation in the reviewed German venue data was EUR 0.29 on Tradegate BSX at 8:02 p.m. CEST on September 18, 2026. Cosmos Health stock therefore combines a small-cap market profile with measurable revenue expansion, but the latest reported loss keeps the operating-growth story tied to future margin improvement.